Intravenous Ampicillin/Sulbactam in Critically Ill Dogs has Variable Pharmacokinetics
Journal of Veterinary Pharmacology and Therapeutics · 2025
DOI: 10.1111/jvp.70004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2025. Verfasst von Robert Goggs und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA. Hauptthemen laut MEDLINE: Sulbactam, Ampicillin, Anti-Bacterial Agents, Dog Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Cornell University.
Abstract (Originalsprache)
Achieving therapeutic plasma concentrations is essential for effective antimicrobial drug (AMD) treatment. Critical illness alters drug distribution and clearance, potentially impacting AMD effectiveness. We conducted a prospective observational study in 25 critically ill dogs to evaluate the pharmacokinetics (PK) of intravenous (IV) ampicillin/sulbactam and achievement of the efficacy target of ≥ 50% of the dosing interval with unbound plasma drug concentrations above the minimum inhibitory concentration ( f T > MIC). All dogs received IV ampicillin/sulbactam from a commercial formulation at a dosage of 20 mg/kg ampicillin/10 mg/kg sulbactam. Plasma concentrations were measured using liquid chromatography–mass spectrometry. PK modeling determined best‐fit compartmental models, and Monte Carlo simulations evaluated the probability of target attainment for bacterial MICs. A one‐compartment model best described ampicillin PK, while a two‐compartment model fit sulbactam. Monte Carlo simulations indicated a 90% probability that ampicillin at 20 mg/kg IV q8 h would achieve the Clinical and Laboratory Standards Institute (CLSI) veterinary breakpoint of 0.25 μg/mL for > 50% of the dosing interval. There was only a 10% probability of achieving the human breakpoint of 8 μg/mL. At 0.25 μg/mL, most Enterobacterales isolates would be resistant. The ampicillin/sulbactam dosage tested meets veterinary CLSI standards for ampicillin but might not effectively treat Enterobacterales infections in critically ill dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
- Comparative Coagulation Laboratory, Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada.
- Department of Molecular Biomedical Sciences, NC State University, Raleigh, North Carolina, USA.
ORCID-Profile: Robert Goggs, Julie Menard, Jeff Beverly
Förderung
- Cornell University
Zitieren
APA
Goggs, R., Robbins, S., Menard, J., Selman, J., Beverly, J., Kraus-Malett, S., & Papich, M. G. (2025). Intravenous Ampicillin/Sulbactam in Critically Ill Dogs has Variable Pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.70004
Vancouver
Goggs R, Robbins S, Menard J, Selman J, Beverly J, Kraus-Malett S, et al. Intravenous Ampicillin/Sulbactam in Critically Ill Dogs has Variable Pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics. 2025. doi:10.1111/jvp.70004
BibTeX
@article{Goggs2025,
author = {Goggs, Robert and Robbins, Sarah and Menard, Julie and Selman, Jamie and Beverly, Jeff and Kraus-Malett, Sydney and Papich, Mark G},
title = {Intravenous Ampicillin/Sulbactam in Critically Ill Dogs has Variable Pharmacokinetics},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2025},
doi = {10.1111/jvp.70004}
}
EUVIMED